Apollon Wealth Management LLC Sells 276 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Apollon Wealth Management LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,999 shares of the biopharmaceutical company’s stock after selling 276 shares during the quarter. Apollon Wealth Management LLC’s holdings in Gilead Sciences were worth $2,264,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. raised its stake in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 238 shares in the last quarter. nVerses Capital LLC bought a new position in Gilead Sciences in the third quarter worth about $25,000. Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Cedar Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $33,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 in the last three months. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

GILD opened at $92.63 on Thursday. The business has a 50 day moving average price of $85.95 and a two-hundred day moving average price of $75.57. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a market capitalization of $115.32 billion, a price-to-earnings ratio of 1,029.22, a price-to-earnings-growth ratio of 2.91 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.11 and a quick ratio of 0.82.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the business posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Wells Fargo & Company boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Royal Bank of Canada increased their price target on Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Eleven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $91.50.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.